- IN₹1.71bn
- IN₹2.99bn
- IN₹3.39bn
- 68
- 46
- 40
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.48 | ||
| Price to Tang. Book | 3.19 | ||
| Price to Free Cashflow | 12.85 | ||
| Price to Sales | 0.54 | ||
| EV to EBITDA | 9.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 18.32% | ||
| Return on Equity | 10.99% | ||
| Operating Margin | 6.89% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 1,710.94 | 2,505.29 | 2,812.14 | 3,042.16 | 3,392.2 | n/a | n/a | 8.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +10.97 | -56.15 | +185.52 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Directors
- Akash Mathur CEO
- G. Rengarajan CFO
- Shailesh Siroya MDR (45)
- Sarika Bhandari DRC
- Jatish Sheth NED
- C.V Srinivas NID (53)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 19th, 1987
- Public Since
- February 1st, 1995
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 15,920,872
- Address
- Four Mangoe Lane, BANGALORE, 560052
- Web
- https://www.balpharma.com/
- Phone
- +91 8041379500
- Auditors
- SS J N B & CO
Upcoming Events for BALPHARMA
Q1 2026 Bal Pharma Ltd Earnings Release
Bal Pharma Ltd Annual Shareholders Meeting
Similar to BALPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Bal Pharma share price?
As of Today at 19:29 UTC, shares in Bal Pharma are trading at IN₹107.14. This share price information is delayed by 15 minutes.
How has the Bal Pharma share price performed this year?
Shares in Bal Pharma last closed at IN₹107.14 and the price had moved by +8.99% over the past 365 days. In terms of relative price strength the Bal Pharma share price has outperformed the S&P BSE 100 Index by +2.67% over the past year.
What are the analyst and broker recommendations for Bal Pharma?
There is no consensus recommendation for this security.
Find out moreWhat is the Bal Pharma dividend yield?
The Bal Pharma dividend yield is 1.12% based on the trailing twelve month period.
Does Bal Pharma pay a dividend?
Last year, Bal Pharma paid a total dividend of IN₹1.20, and it currently has a trailing dividend yield of 1.12%. We do not have any data on when Bal Pharma is to next pay dividends.
When does Bal Pharma next pay dividends?
We do not have data on when Bal Pharma is to next pay dividends. The historic dividend yield on Bal Pharma shares is currently 1.12%.
How do I buy Bal Pharma shares?
To buy shares in Bal Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bal Pharma?
As of the previous close price of IN₹107.14, shares in Bal Pharma had a market capitalisation of IN₹1.71bn.
Where are Bal Pharma shares listed?
Here are the trading details for Bal Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BALPHARMA
What kind of share is Bal Pharma?
Based on an overall assessment of its quality, value and momentum Bal Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bal Pharma share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Bal Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bal Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -4.2%.
As of the last closing price of IN₹107.14, shares in Bal Pharma were trading -8.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bal Pharma PE Ratio?
The Bal Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹107.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bal Pharma?
Bal Pharma's management team is headed by:
- Akash Mathur - CEO
- G. Rengarajan - CFO
- Shailesh Siroya - MDR
- Sarika Bhandari - DRC
- Jatish Sheth - NED
- C.V Srinivas - NID